logo
BA
Brian Abrahams
Analyst at RBC Capital
USA
Ticker Coverage
BCRX
Sector Coverage
Mentions in the News
Better Buy: Gilead Sciences vs. Biogen
Which stock wins in a battle between these two big biotechs?
Published: Sep 1 2019
Amgen Stock Rises On Deal To Buy Celgene's Drug Otezla For $13.4 Billion - Investor's Business Daily
Amgen Stock Rises On Deal To Buy Celgene's Drug Otezla For $13.4 Billion Investor's Business Daily Why Amgen Thinks Celgene's Psoriasis Drug Otezla Is Worth $13.4 Billion Bloomberg Markets and Finance Bristol-Myers Moves Closer to Buying Celgene The Wall Stre…
Published: Aug 26 2019
Celgene to Sell Blockbuster Drug to Amgen for $13B to Close BMS Deal
Celgene is selling a blockbuster anti-inflammatory drug to Amgen for $13.4 billion cash, a deal needed to close the company’s pending $74 billion acquisition by Bristol-Myers Squibb. Bristol-Myers (NYSE: BMY) is still working to complete the proposed acqui…
Published: Aug 26 2019
Show More..
Would you like to be included in the directory? Let us know!
exchange@streetcontxt.com
© Street Contxt. All Rights Reserved.
Privacy